Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Seeking Recovery for Investors - Contact The Gross Law Firm

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to allegations of misleading statements and failure to disclose material adverse facts about the company's growth potential [1]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from August 8, 2024, to May 8, 2025, Iovance provided overly positive statements while concealing significant issues regarding its ability to meet demand for its treatments [1]. - Key factors leading to the company's reduced revenue guidance included maintenance of the iCTC, lower than expected Proleukin sales, and the variable pace of treatment initiation by ATCs [1]. Financial Impact - Following the announcement of reduced revenue guidance on July 25, 2024, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to$1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [1]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [3].